Home
Centre for Cancer Biomarkers CCBIO

News archive for Centre for Cancer Biomarkers CCBIO

The Norwegian Society of Pathology celebrated the first 100 years with a symposium on Updates and Future of Pathology. The event was supported by CCBIO and also celebrated with a history book covering the Society and its activities through 1923-2023.
CCBIO PhD candidate Marta Espevold Hjelmeland in the Krakstad group spends the second year of her PhD program in Boston.
The regional health authority Helse Vest’s Research Award 2023 goes to Professor Lars Andreas Akslen and CCBIO for ground-breaking research on cancer biomarkers. Akslen has also been subject to another prestigious recognition this fall, as he was recently elected as member of the Academia Europaea.
Mari Kyllesø Halle received a frame allocation of NOK 8 million in the Researcher Projects 2023 call from the Norwegian Cancer Association, for the project "Decoding the Landscape of Cancer Vulnerabilities in high-risk Cervical Carcinomas to detect new treatment strategies." CCBIO is proud to see this CCBIO Masterclass alumna as a project leader for the first time.
Emmet McCormack will be part of the new COST Action IMMUNO-model, where a network of scientists involved in the development and implementation of preclinical models evaluating the response and toxicity induced by immunotherapies, is challenged to expand our knowledge in their mechanisms of action and improve the survival and quality of life of cancer patients.
Forsker Grand Prix took place in Bergen September 27, where nine young researchers were competing for Best Presenter, getting only four minutes to convey their research in front of an audience and three judges. Among the nine was CCBIO's and the Department of Clinical Science's PhD Candidate Christiane Helgestad Gjerde.
The 11th CCBIO Annual Symposium was this time enlarged with a generous time frame and two overnight stays, May 8-11, 2023. Although there was an option for online attendance, only 14 participants chose to attend online, and the rest of the total of 235 chose to enjoy the company of colleagues and the informal and mutually fertilizing scientific crosstalk in the breaks and the evenings.
This winter/spring, three of CCBIO's students got the opportunity to have research stays at different labs of the Vascular Biology Program in Boston, through CCBIO's INTPART collaboration with Harvard Medical School and Boston Children's Hospital. PhD Candidate Camilla Tvedt Ekanger, Medical Student Research Program student Amalie Bark Kvamme and PhD Candidate Ole Vidhammer Bjørnstad are now back... Read more
A simple blood test can contribute to earlier detection of cancer and provide valuable information about the tumor in a number of cancers. The technology behind liquid biopsies is still being tested, but will change the landscape in cancer diagnostics, says professor and CCBIO-partner Klaus Pantel.
In his opening lecture of the 2023 General Assembly at the Vatican City, UiB professor Roger Strand explored the role of ethics in converging technologies.
The research group of Professor Daniela Costea is currently engaged in a DIKU/NORPART funded collaboration project with partners in Tanzania, establishing immunohistochemistry for p16 as a method for more precise diagnostic of head and neck cancers (HNC). CCBIO has just had a visit from Tanzania, and Professor Costea has just returned from a 2 week stay in Dar Es Salaam where she worked with... Read more
The INTPART-II Flagship-course CCBIO907 Cancer-Related Vascular Biology took place in Bergen March 24th to March 31st 2023, with fortunate students from UiB and a couple of visiting students from abroad who got the opportunity to learn from and connect with excellent Harvard Medical School faculty on campus in Bergen.
CCBIO would like to highlight recent publications in high impact journals.
Acute myeloid leukemia is an aggressive blood cancer with poor survival. Younger and otherwise healthy patients undergo severe chemotherapy, often accompanied by stem cell transplant, even though it is difficult to predict who will benefit from the treatment. Now, a simple blood test can measure whether the patient's cancer will respond to chemotherapy. If the chemo has no effect, critical weeks... Read more
The Norwegian Cancer Society has a new funding program, the Norwegian Cancer Society Pioneer Projects, which supports early-stage exploration of novel and innovative ideas with potential for breaking new grounds in cancer research. CCBIO Associate Investigator Carina Strell just got the news that she is awarded with funding from this program for her project "ImSignal – Mapping active immune... Read more
Professor Arne Östman in CCBIO's International Faculty receives financial support from the Western Norway regional health authorities Helse Vest in their 2023 allocation. His project "Novel biomarkers and combination treatments for ER+ breast cancer" receives NOK 1.500.000 in the first year.
November 26, the regional health authorities Helse Vest announced their funding for 2023, allocating 182 million NOK to 57 new projects, and renewed support to 160 fellows and projects. Among the new projects, CCBIO PI Oddbjørn Straume receives open project support for his project "Targeting AXL to improve immunotherapy: Deep clinical biomarker analysis for precision medicine." The funding... Read more
CCBIO hosted the 6th SCANPATH meeting – Scandinavian Seminar on Translational Pathology – on November 14 and 15 at Solstrand Hotel, close to Bergen (Norway). Top Scandinavian tumor pathologist and pre-clinical scientists came to present and discuss tissue-based studies of tumor mechanisms and biomarker mapping. SCANPATH is a well-established annual forum and has been a successful CCBIO initiative... Read more

Pages